EZI activators, or Enhancer of Zeste Inhibitor activators, are a class of chemical compounds that specifically interact with a family of proteins known as Polycomb-group (PcG) proteins. PcG proteins are involved in the regulation of gene expression through the modification of chromatin structure, which is the complex of DNA and protein found in the nucleus of eukaryotic cells. One of the key components of this protein family is the Enhancer of Zeste homolog 2 (EZH2), which acts as a methyltransferase, transferring methyl groups to histone proteins-the core components around which DNA is wound. This methylation is a critical process in the epigenetic regulation of genes, playing an essential role in the control of gene activation and repression. EZI activators are designed to modulate the activity of EZH2, thereby influencing the methylation status of histones and ultimately affecting the expression pattern of genes.
The molecular design of EZI activators is rooted in the understanding of the enzymatic mechanism of EZH2. By binding to the catalytic site or allosteric sites of EZH2, these activators can modulate the activity of the enzyme. The structure-activity relationship (SAR) of these molecules is an active area of research, focusing on optimizing the interactions between the EZI activators and EZH2 proteins to achieve desired modulation effects. These compounds are often characterized by their ability to influence the tri-methylation state of histone H3 on lysine 27 (H3K27me3), which is a hallmark of EZH2 enzymatic activity. Understanding the precise mechanism by which EZI activators exert their effect on EZH2 involves detailed studies of molecular biology, biochemistry, and structural biology to elucidate the interaction between these small molecules and their target protein at the atomic level.
Items 11 to 12 of 12 total
디스플레이 라벨:
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580은 p38 MAPK의 특정 억제제입니다. p38 MAPK는 다양한 신호 경로를 부정적으로 조절할 수 있기 때문에 p38을 억제함으로써 EZI를 활성화할 수 있는 경로에 대한 세포 신호의 균형을 바꿀 수 있습니다. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
탑시갈긴은 소포체/소포체 Ca2+ ATPase(SERCA)의 억제제로 세포질 칼슘 수치를 증가시킵니다. 칼슘이 증가하면 칼슘 의존적 신호 전달 경로가 활성화되어 EZI의 활성을 간접적으로 향상시킬 수 있습니다. |